The Complete Guide to HGH Therapy for Men

Human growth hormone therapy is one of the most misunderstood treatments in men’s health — simultaneously overhyped in wellness circles and underutilized in men who genuinely need it. The gap between the marketing narrative (“anti-aging miracle”) and the clinical reality (a well-evidenced treatment for a specific hormonal deficiency) leaves most men without a clear picture of what HGH therapy actually is, who it’s for, what it does, and how it works.

This guide covers everything: the physiology of growth hormone, how deficiency develops and is recognized, what the diagnosis requires, the full range of treatment options, the evidence on outcomes, the risks, the costs, and how HGH therapy fits alongside other hormonal treatments. It’s written for men who want the clinical reality — not the marketing version.

What Is Human Growth Hormone?

Human growth hormone (GH, also called somatotropin) is a peptide hormone produced by somatotroph cells in the anterior pituitary gland. It is released in pulses throughout the day — with the largest pulse occurring shortly after the onset of deep sleep — under the control of two hypothalamic hormones: growth hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which inhibits it.

GH exerts its effects both directly — acting on GH receptors in fat cells, immune cells, and other tissues — and indirectly through insulin-like growth factor 1 (IGF-1), which the liver produces in response to GH. IGF-1 mediates most of GH’s anabolic effects on muscle, bone, and connective tissue.

In adult men, growth hormone is not primarily about growth — the linear growth plates have closed. Its role in adults is metabolic and compositional: it regulates fat mobilization (particularly visceral fat), lean mass maintenance, bone density, cardiovascular function, glucose metabolism, and quality of life parameters including energy, mood, and cognitive function.

The natural decline of GH with age

GH secretion peaks in adolescence and declines steadily from the mid-20s onward — at roughly 14% per decade on average. By age 60, most men secrete approximately one-third of the GH they produced at 20. This is a normal physiological change — it does not constitute a disease and does not require treatment in healthy aging men.

What requires treatment is confirmed adult growth hormone deficiency (AGHD) — a clinical condition defined by inadequate GH secretion below established thresholds on standardized testing, in the context of relevant history and symptoms. This is a distinct entity from normal age-related GH decline.

Adult Growth Hormone Deficiency: Who Gets It and Why

AGHD in men occurs when the hypothalamic-pituitary-somatotropic axis fails to produce adequate GH. The causes are more specific than “getting older.”

Primary causes

• Pituitary adenomas — the most common cause; benign pituitary tumors compress somatotroph cells, reducing GH secretion
• Pituitary surgery — treatment of pituitary tumors frequently damages GH-secreting cells even when the tumor is successfully removed
• Cranial radiation — radiation therapy to the brain or pituitary for tumors (including those outside the pituitary) damages the hypothalamic-pituitary axis; GH secretion is often the first hormone affected
• Traumatic brain injury (TBI) — the pituitary sits in a bony structure vulnerable to TBI; moderate-to-severe TBI can impair GH secretion in a significant proportion of survivors
• Infiltrative diseases — sarcoidosis, hemochromatosis, histiocytosis X can infiltrate the pituitary and hypothalamus
• Idiopathic — no identifiable structural cause; accounts for a proportion of confirmed AGHD cases

The critical clinical point: AGHD in adults is almost always caused by an identifiable pituitary or hypothalamic pathology. This is why stimulation testing — not just a low IGF-1 — is required for diagnosis. It’s also why the treatment decision involves specialist evaluation, not a simple blood panel.

For the signs that suggest GH deficiency may be present, the 7 signs of low growth hormone covers the clinical presentation in practical detail.

Recognizing AGHD: Symptoms in Adult Men

The clinical picture of adult GH deficiency is meaningful but non-specific — it overlaps significantly with testosterone deficiency, hypothyroidism, depression, and normal aging. No single symptom confirms the diagnosis.

The symptom overlap with testosterone deficiency is clinically important. Men with pituitary pathology often have both GH and testosterone deficiency simultaneously — because the pituitary controls both axes. In these men, treating only testosterone without evaluating GH status leaves a significant component unaddressed. The full comparison of how the two deficiencies differ and interact is in the HGH vs TRT guide. For a full overview of hormonal symptoms that don’t always get recognized as such, the article on fatigue, irritability, and low libido in men over 50 covers the broader picture.

Diagnosis: What AGHD Confirmation Actually Requires

This is where HGH therapy diverges most clearly from TRT — the diagnostic bar is significantly higher, and for good clinical reason.

Step 1: Screening — IGF-1

The first-line screen for GH axis function is serum IGF-1. Because GH is released in pulses and fluctuates throughout the day, a single GH measurement is unreliable. IGF-1 — produced by the liver in response to GH and reflecting overall GH exposure over hours — is a more stable and useful screening marker.

A low IGF-1 in the context of relevant history (pituitary disease, TBI, radiation) raises suspicion for AGHD but does not confirm it. IGF-1 can be low due to malnutrition, liver disease, hypothyroidism, or other causes independent of GH axis function.

Step 2: Stimulation testing — the diagnostic gold standard

Confirmed AGHD diagnosis requires a dynamic GH stimulation test — a procedure that pharmacologically stimulates GH release and measures the peak GH response. The most commonly used tests include:

• Insulin tolerance test (ITT) — considered the gold standard; insulin-induced hypoglycemia is a potent GH stimulus; peak GH below 5 μg/L confirms AGHD in most guidelines
• Glucagon stimulation test — used when ITT is contraindicated (cardiac disease, seizure history); generally acceptable alternative with established cutoffs
• Macimorelin (Macrilen) — FDA-approved oral GH stimulation test; newer option that avoids the risks of ITT; increasingly used in clinical practice

These tests require monitoring in a clinical setting — they can’t be done with a home kit or through a mail-order lab. This is a meaningful barrier to diagnosis that appropriately filters out men who don’t have true AGHD from those who do.

One exception: men with multiple confirmed pituitary hormone deficiencies (e.g., confirmed panhypopituitarism with at least 3 additional deficiencies) may be diagnosed with AGHD based on low IGF-1 alone, without requiring stimulation testing — per current Endocrine Society guidelines.

FDA-Approved Indications for HGH Therapy

In adults, recombinant human growth hormone (rhGH) is FDA-approved for a specific list of conditions — not for general anti-aging or wellness use.

Table 1 — FDA-approved HGH indications in adults. Prescribing HGH for anti-aging or weight loss without a confirmed medical indication is explicitly prohibited under U.S. law. For more on HGH and body composition, see the HGH therapy for weight loss evidence guide.

HGH Therapy: How Treatment Works

The medication: recombinant human growth hormone

HGH therapy uses recombinant human growth hormone (rhGH) — a synthetic version of the 191-amino-acid GH molecule produced using recombinant DNA technology. Multiple FDA-approved brands are available (Norditropin, Genotropin, Humatrope, Omnitrope, Saizen, and others), all containing the same active molecule at equivalent potency.

Administration

rhGH is administered via daily subcutaneous injection — typically in the evening to align with the body’s natural GH pulse during sleep. Modern delivery devices (autoinjector pens) make self-injection simple, and the needles are small enough that most patients describe the experience as minor.

The daily injection requirement is one of the practical differences from testosterone therapy, which can be administered weekly, every two weeks, or every 3–6 months with pellets. For men who manage TRT alongside HGH therapy, the daily injection cadence of HGH is an additional commitment to incorporate into daily routine.

Dosing and titration

Starting doses in AGHD are conservative — typically 0.1–0.3 mg/day — and titrated upward gradually based on IGF-1 response and clinical symptoms. The goal is to restore IGF-1 to the middle of the age-adjusted normal range — not to maximize it. Supraphysiological IGF-1 increases side effect risk without proportional clinical benefit.

Titration occurs over 4–6 months, with IGF-1 measured at each adjustment. Once a stable therapeutic dose is established, monitoring frequency decreases to every 6–12 months for ongoing surveillance.

Monitoring during HGH therapy

Standard monitoring for confirmed AGHD on HGH therapy includes:

• IGF-1 — at every dose adjustment; every 6 months once stable
• Fasting glucose and HbA1c — GH has insulin counter-regulatory effects
• Lipid panel — body composition changes affect lipid profiles
• Bone density (DEXA) — annually in men with confirmed deficiency and BMD concern
• Clinical assessment of symptoms, quality of life, and side effects

What HGH Therapy Actually Does: Evidence-Based Outcomes

The clinical evidence for HGH replacement in confirmed AGHD is robust and consistent across multiple randomized controlled trials and long-term cohort studies.

The body composition and quality-of-life improvements are the most consistently documented and clinically meaningful benefits. The body composition effects of HGH in AGHD — specifically visceral fat reduction with lean mass preservation — are explored in greater depth in the article on HGH therapy and weight loss evidence.

Risks and Side Effects: What to Know

HGH therapy at physiological doses in confirmed AGHD has a well-characterized safety profile. Side effects are predominantly dose-dependent and manageable with appropriate titration.

Common side effects (dose-dependent)

• Fluid retention (edema) — the most common initial side effect; ankle swelling or peripheral puffiness; typically resolves with dose reduction or as the body adjusts
• Arthralgias and myalgias — joint and muscle aches, particularly in larger joints; dose-dependent; more common at higher starting doses
• Carpal tunnel syndrome — fluid shifts affecting the wrist can compress the median nerve; resolves with dose reduction in most cases
• Headache — more common in early treatment; typically transient

Metabolic considerations

GH has counter-regulatory effects on insulin — meaning it can worsen insulin sensitivity at higher doses. Fasting glucose and HbA1c are monitored throughout therapy. Men with pre-existing diabetes or significant insulin resistance require more careful dose management and closer monitoring. At therapeutic physiological doses, the metabolic concern is manageable for most men.

The cancer question

IGF-1 is a growth factor with known mitogenic properties — meaning it can stimulate cell proliferation. This raised theoretical concerns that HGH therapy might increase cancer risk. Long-term surveillance data from confirmed AGHD populations does not show a significantly elevated cancer incidence at therapeutic doses in the general AGHD population. HGH therapy is contraindicated in men with active malignancy and requires individualized evaluation in men with a history of cancer.

HGH Therapy vs. GH Secretagogue Peptides

For men who are interested in GH axis support but don’t meet the diagnostic criteria for confirmed AGHD, growth hormone secretagogue peptides offer an alternative that stimulates the pituitary to produce more of its own GH — rather than replacing it directly.

Table 2 — HGH therapy vs. GH secretagogue peptides. The right approach depends on whether true AGHD is confirmed and whether the pituitary is capable of responding to stimulation. For a detailed peptide comparison including Sermorelin, CJC-1295, and BPC-157, see the peptide comparison guide.

HGH Therapy Alongside TRT: The Combined Picture

For men with pituitary pathology who have both testosterone deficiency and GH deficiency — a common presentation — combined therapy addressing both axes produces meaningfully better outcomes than treating either in isolation.

Testosterone and GH are complementary in their effects on body composition: testosterone drives protein synthesis in muscle through androgen receptors, while GH/IGF-1 promotes fat mobilization and connective tissue support. Their anabolic signaling pathways are distinct but synergistic. Men on TRT whose body composition, energy, and quality of life don’t fully normalize despite optimized testosterone levels should have GH axis evaluation considered.

For men starting TRT evaluation who want to understand how GH fits into the broader hormonal picture, the complete TRT guide covers the testosterone side in full, and the HGH vs TRT comparison covers the differential diagnosis and how to determine which — or both — is needed.

Frequently Asked Questions

How do I know if I need HGH therapy?

The starting point is clinical history — particularly any history of pituitary disease, brain surgery, cranial radiation, or traumatic brain injury. These are the highest-risk factors for AGHD. Symptoms alone (fatigue, body composition changes, reduced quality of life) are not sufficient for diagnosis but are appropriate reasons to seek evaluation. A physician begins with an IGF-1 blood test and, if indicated, proceeds to a formal GH stimulation test. You cannot self-diagnose AGHD or confirm it with a consumer lab test.

What is the difference between HGH therapy and peptides like Sermorelin?

HGH therapy directly replaces growth hormone — bypassing the pituitary entirely. Sermorelin and similar peptides (CJC-1295, Ipamorelin) stimulate the pituitary to produce more of its own GH. The distinction matters because: men with confirmed pituitary damage may not respond to peptide stimulation (the pituitary can’t respond); men with functioning pituitaries and sub-optimal rather than severely deficient GH may benefit from peptides without needing direct HGH replacement. For the full comparison, the peptide guide covers this in detail.

Is HGH therapy the same as “anti-aging” GH treatments?

No. FDA-approved HGH therapy for confirmed AGHD is a medical treatment for a documented hormonal deficiency. “Anti-aging” GH use — prescribing HGH to healthy adults without confirmed deficiency — is explicitly not FDA-approved and is illegal under U.S. law when marketed for that purpose. The evidence for GH in non-deficient adults shows modest effects at best and a worse side effect profile than in AGHD populations. The marketing language often blurs this distinction; the clinical and regulatory reality does not.

How long does it take to see results from HGH therapy?

The titration phase typically takes 4–6 months before a stable therapeutic dose is established. Meaningful body composition changes — particularly visceral fat reduction — become measurable at 3–6 months of consistent therapy. Quality of life and energy improvements are often noticed earlier. Bone density changes require 12–24 months to register on DEXA. Maximum benefits generally accumulate over 18–24 months of sustained treatment.

What does HGH therapy cost?

Recombinant HGH is one of the more expensive prescription therapies — typically $3,000–$15,000+ annually without insurance, depending on dose, brand, and pharmacy. Men with confirmed AGHD and documented pituitary pathology may have coverage through private insurance or Medicare Part D, though prior authorization requirements are stringent. The financial reality is one reason the diagnostic threshold for AGHD is important — it focuses therapy on men with confirmed need.

Can I get HGH therapy online?

Not appropriately. Confirmed AGHD requires a GH stimulation test — which cannot be administered remotely. Men who receive “HGH therapy” through online telemedicine platforms without stimulation testing have not been properly diagnosed and are receiving off-label prescribing outside clinical guidelines. This is different from online TRT, where the diagnostic workup (two fasting morning testosterone draws) can be done through a local lab and results reviewed remotely. HGH therapy requires in-person specialist involvement for appropriate diagnosis.

Will HGH therapy help me lose weight?

In confirmed AGHD, yes — it produces meaningful visceral fat reduction and body composition improvement. In men without confirmed deficiency, the evidence is much weaker and the side effect risk is higher. HGH is not FDA-approved for weight loss. For men whose primary concern is weight management without a GH deficiency context, GLP-1 therapies (semaglutide, tirzepatide) have a significantly stronger evidence base and regulatory approval for this indication. The full evidence review is in the HGH and weight loss evidence guide.

Is HGH therapy permanent?

For men with structural pituitary disease, GH secretion is unlikely to recover — ongoing therapy is typically required for as long as the clinical benefits and patient preference support continuation. Annual benefit-risk reassessment is standard practice. Some men — particularly those who began HGH therapy after TBI — may show partial recovery of GH secretion over time, at which point dose reduction or discontinuation may be considered with physician guidance.

References

1. Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587–1609. doi:10.1210/jc.2011-0179
2. Yuen KCJ, Biller BMK, Radovick S, et al. AACE/ACE Guidelines for Management of Growth Hormone Deficiency in Adults. Endocr Pract. 2019;25(11):1191–1232. doi:10.4158/GL-2019-0405
3. Hazem A, Elamin MB, Bancos I, et al. Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol. 2012;166(1):13–20. doi:10.1530/EJE-11-0558
4. Gotherstrom G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults. J Clin Endocrinol Metab. 2001;86(10):4657–4665. doi:10.1210/jcem.86.10.7887
5. Johannsson G, Mårtensson M. Growth hormone — health and longevity in adults. Growth Horm IGF Res. 2018;38:28–32. doi:10.1016/j.ghir.2017.12.002
6. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104–115. doi:10.7326/0003-4819-146-2-200701160-00005
7. U.S. Food & Drug Administration. Approved Drug Products: Human Growth Hormone. accessdata.fda.gov